Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company.
The deal is valued at 737.3 billion won and is valid till December 2031, the contract development and manufacturing organization said in a regulatory filing on Monday with Korea Exchange.
Shares of Samsung Biologics rose nearly 1% in recent trade on Tuesday, April 29.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。